IL16 and Miyoshi myopathy: Indeed, blocking of IL-16 using a neutralizing antibody led to a dose-dependent reduction in the proliferative activity of MM cells compared to an isotype control antibody as determined by 3H-thymidine incorporation (Figure 1G).